Research
Hormonal
Semaglutide improves cardiovascular risk factors, including blood pressure and heart failure symptoms, in patients with obesity.
Semaglutide may help lower blood pressure and improve heart function in obese patients with heart failure, in addition to aiding weight loss.
GoodSupportsHIGH confidence
Semaglutide (2.4 mg) administered once a week demonstrated to improve symptoms related to heart failure (HF), physical limitations, body weight, and functional capacity in patients with heart failure associated with obesity and preserved ejection fraction (HFpEF)... Semaglutide also demonstrated high efficacy in reducing blood pressure...
Why this rating
Cites STEP-HFpEF and other studies.
Source
Avaliação do reposicionamento farmacológico da semaglutida no processo de emagrecimento: Uma revisão da literatura
Juliano Policarpio Moura et al. · Research Society and Development · 2024
DOI 10.33448/rsd-v13i11.47305
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide 2.4 mg administered once weekly produces significant weight loss (mean 14.9%) in adults with obesity or overweight, superior to placebo, when combined with lifestyle interventions.Good
- Discontinuation of semaglutide leads to partial weight regain, indicating that continuous treatment is necessary to maintain weight loss results.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →